2 results
Not approvedWill not start
The purpose of this study is the evaluation of InPen* with InPen* 2.0 app and Guardian* 4 system in adult patients with type 1 diabetes for the design of a future study.
Approved WMORecruiting
The anti-TIM-3 monoclonal antibody MBG453 is a novel immunotherapeutic agent with promising activity seen in AML and MDS. The purpose of the current study is to assess clinical effects of MBG453 in combination with azacitidine in adult subjects with…